Abstract
Introduction: Axillary ultrasound (AUS) for axillary staging of breast cancer is a standard procedure now to identify metastatic lymph nodes (LN). In 2009 we retrospectively audited AUS for axillary staging and found a sensitivity of 57.7% and specificity of 92.7% in our breast unit. However, only 50% of abnormal nodes were AUS-guided biopsied. In this study we aim to close the audit cycle by assessing whether the prevalence of AUS has increased and more abnormal nodes have been biopsied.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
